Insmed price target raised to $40 from $37 at Barclays

Barclays raised the firm’s price target on Insmed to $40 from $37 and keeps an Overweight rating on the shares. The analyst sees “compelling reasons to be optimistic” on treprostinil palmitil inhalation powder in pulmonary hypertension, with potential for over $1.5B peak sales “under very conservative/beatable assumptions.” The path to market will take time, but the risk is low, the analyst tells investors in a research note.